Jefferies begins coverage of MDS at buy

Jefferies & Co., Inc. analyst David Windley started coverage of MDS Inc. with a buy rating and a price target of $24. The company offers investors exposure to the growing contract research organization, radioisotopes and analytical instruments markets. Shares of the Toronto-based life sciences company were up $1.16, or 6.93%, at $17.89. (NYSE: MDZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.